<DOC>
	<DOCNO>NCT00426673</DOCNO>
	<brief_summary>The primary objective Phase I study 15 adult subject suffer epilepsy chronically treat phenytoin monotherapy evaluate effect steady-state ucb 34714 administration steady-state plasma level phenytoin .</brief_summary>
	<brief_title>An Open-Label Interaction Study Look Effects Brivaracetam Phenytoin When Taken Together 15 Adult Patients With Epilepsy .</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Phenytoin</mesh_term>
	<criteria>Wellcharacterized epileptic syndrome accord ILAE classification . Patients currently treat stable phenytoin monotherapy least three month least one plasma measurement pheyntoin within target range ( 7 23 µg/ml ) screening period . History status epilepticus last year . Subjects take drug may significantly influence metabolism ucb 34714 ( CYP2C CYP3A potent inducers/inhibitors ) except dose stable least three month entry study keep stable entire trial duration . Subjects creatinine clearance ≤50 mL/min .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>partial onset seizure , phenytoin , dilatin , brivaracetam , interaction</keyword>
</DOC>